Exclusive Pennsylvania Partners
Collin Palmer is a life long resident of Pennsylvania, splitting his time between CA, NY and PA. Mr Palmer has over 16 years of experience spanning a diverse range of disciplines in production, marketing and advertising with a sharp eye for leadership. Mr. Palmer has been apart of building some of the worlds biggest brands and bringing products to market for clients such as, Viacom, Toyota, Chrysler , Philips, Canon, P&G and Unilever handling global accounts across several verticals from full global commercial campaigns all the way to beauty products, he has the ability to lead large teams with clarity across verticals. Mr. Palmers unique understanding of market trends and data are one of his keys principles to building a company focused on the patients needs rather then following trends. Additionally, Mr. Palmer has been featured in Rollingstone, I-D , ELLE and Esquire for his creative insight.
Partner, Cultivar, United Cannabis
Earnest Blackmon is a horticulturalist and entrepreneur with over 20 years experience, including 5 years in the Commercial Cannabis Industry. Mr. Blackmon is currently an owner and the master grower at RiverRock Colorado and is responsible for the production, processing, workflow management, JIT inventory control, security, staffing, training and recruiting. Mr. Blackmon has developed a proprietary grow method based on an organic standard to aid in stable chemical synthesis to limit side reactions that diminish yield. Mr. Blackmon’s skill with operations, project management, quality control and cultivation insure that every United Cannabis production facility produces consistent high grade organic cannabis to meet the demands of our patients.
Partner, Terpene Extraction, BlueRiver Extracts
Tony Verzura oversees the A.C.T. Now Program, product manufacturing, quality assurance, product development, product training, staffing, and brand awareness. Mr. Verzura works hand in hand with the affiliated partners to help coordinate on boarding patient programs, standard operating procedures, and ensures company goals are being met worldwide. Mr. Verzura has been apart of over 30 Awards worldwide, including 5x 1st Place CBD Concentrate Awards, and has been featured on CNBC Money Talk as an honorary guest speaker. He has attended countless cannabis business conferences and events throughout the United States, Jamaica, Canada, Amsterdam, and Spain. He is a weekly panelist on the highly publicized educational YouTube show called Hash Church hosted by Bubbleman’s World. His publications include The Washington Post, High Times, Culture Magazine, DOPE Magazine, Skunk Magazine, Sensi Seeds, and Frank 151.
Brent A. Reynolds
UCANN Chief Medical Advisor - Prana / Ucann
Brent A. Reynolds, Ph.D., attended the University of Calgary, where he received his M.Sc. and Ph.D. in 1989 and 1994, respectively. While working on his Ph.D. thesis Reynolds co-discovered the existence of stem cells in the adult mammalian brain, a finding that overcame a century old dogma that the mature brain did not have the capacity to repair itself. After graduating, Reynolds co‑founded the first neural stem cell company, NeuroSpheres, Ltd., where he was a director and vice president of research. Here he developed a strong patent portfolio in the neural stem cell field, developing and protecting protocols related to the application of stem cell technology in brain repair. Today, these patents and technology have been licensed to numerous biotechnology companies that are testing the efficacy in over half a dozen clinical trials for diseases such as spinal cord injury, stroke, ALS and pediatric disorders. After a brief hiatus, where Reynolds studied and practiced Traditional Chinese Medicine, he returned to industry working with StemCell Technologies in Vancouver, Canada. In 2004, Reynolds returned to academic science as a professor at the Queensland Brain Institute at the University of Queensland in Australia where he continued refining the application of neural stem cells for repairing the damaged brain. In 2008, Reynolds was recruited to the department of Neurosurgery at the University of Florida and has focused his efforts on studying aggressive pediatric and adult brain cancer and developing novel translational approaches to combat this lethal disease. Working with a multidisciplinary group of scientists, the team is taking the unique approach that cancer can be managed as a chronic disease by applying the principles that have been used in ecology to manage wildlife and pest populations. Based on the lessons learned over the past 80 years by ecologists, the team is focused on using multimodal low toxicity therapeutics to enforce a stable tumor population that exists below a threshold that has any harmful effects. Dr. Reynolds has more than 60 publications, including papers in Science, Cell and Nature, with several manuscripts receiving over 1,000 citations. In addition, he is an inventor on 18 granted US patents. Dr. Reynolds is currently a professor in the department of neurosurgery at UF; adjunct professor at the University of New South Wales, Sydney, Australia; an honorary professor at the Queensland Brain Institute, Australia; and program director for StepAhead, Australia. NIH, NHMRC and numerous foundations have funded his lab.
Exclusive Pennsylvania Investors
TheraCann International - Exclusive Partners
TheraCann International Corperation is dedicated to provide Vessel Life Science a collaborative effort harnessing our roots in Benchmark Laboratories Group Ltd. Formed in 2004 for the Common Wealth of Pennsylvana. TheraCann remain true to the same principles on which the company was founded on over a decade ago: Providing Vessel Life Science superior service, putting regulatory requirements and quality assurance first, creating opportunities for clients and vendors,delivering exceptional work, fostering innovation, acting with integrity , and strengthening our corporate sector. The goal is to implement innovative solutions to the worlds most optimized, secure and quality controlled industrial cannabis operations in partnership with Vessel Life Science.